Disc Medicine Reports Promising Phase 1b Trial Results
Company Announcements

Disc Medicine Reports Promising Phase 1b Trial Results

An announcement from Disc Medicine ( (IRON) ) is now available.

Disc Medicine, a biopharmaceutical company, unveiled promising interim results from its Phase 1b trial of DISC-0974 at the ASN Kidney Week 2024. The study showcased significant improvements in anemia markers for patients with non-dialysis-dependent chronic kidney disease (NDD-CKD), demonstrating substantial reductions in hepcidin levels and increases in hemoglobin. DISC-0974’s safety and tolerability were confirmed, highlighting its potential as a treatment for anemia linked to various chronic conditions. These findings suggest DISC-0974’s broader applicability in addressing anemia associated with inflammatory diseases.

For detailed information about IRON stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyDisc Medicine reports Q3 EPS (89c), consensus ($1.05)
TipRanks Auto-Generated NewsdeskDisc Medicine Secures $200M Financing for Hematology Pipeline
TheFlyDisc Medicine secures $200M in non-dilutive debt financing
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App